Status:

COMPLETED

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Pneumococcal Infections

Eligibility:

All Genders

50+ years

Phase:

PHASE2

Brief Summary

The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal Polysaccharide Va...

Eligibility Criteria

Inclusion

  • Without fever for 72 hours prior to vaccination

Exclusion

  • Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate vaccine
  • Known or suspected to be immunocompromised
  • Functional or anatomic asplenia
  • History of autoimmune disease
  • Evidence of dementia or cognitive impairment
  • Use of any immunosuppressive therapy
  • Received a licensed non-live vaccine administered within the 14 days prior to receipt of study vaccine or scheduled to receive any other licensed vaccine within 30 days following receipt of study vaccine
  • Received a licensed live virus vaccine within 30 days prior of receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days of receipt of study vaccine
  • Received any vaccine containing diphtheria toxoid within 6 months prior to receipt of study vaccine
  • Received a blood transfusion or blood products within the 6 months before receipt of study vaccine or scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine
  • History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease
  • Received antibiotic therapy for any acute illness within 72 hours before receipt of study vaccine

Key Trial Info

Start Date :

March 13 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 15 2013

Estimated Enrollment :

692 Patients enrolled

Trial Details

Trial ID

NCT01513551

Start Date

March 13 2012

End Date

February 15 2013

Last Update

December 13 2018

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) | DecenTrialz